Notice of Proposed Sale · 144
Tarsus Pharmaceuticals, Inc.
TARSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- TARSUS PHARMACEUTICALS INC
- Issuer CIK
- 0001819790
- SEC file number
- 001-39614
- Phone
- 949-418-1801
- Person for whose account securities are to be sold
- WILLIAM J LINK
- Relationships to issuer
- DIRECTOR
- Street
- 17700 LAGUNA CANYON ROAD
- Street (continued)
- FLOOR4
- City
- IRVINE
- State / country code
- CA
- Postal code
- 92618
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| COMMON | 12,500 | 979,745.36 | 43,882,996 | 09/15/2026 | NASDAQ | MERRILL LYNCH |
Broker / market maker — proposed row 1, entry 1
- Name
- MERRILL LYNCH
- Street
- 520 NEWPORT CENTER DRIVE 20TH FLOOR
- City
- NEWPORT BEACH
- State / country code
- CA
- Postal code
- 92660
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| COMMON | 01/10/2017 | STOCK OPTION EXERCISE | TARSUS PHARMACEUTICALS INC | 12,500 | N | 01/10/2017 | CASH |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 09/15/2026
- Signed
- WILLIAM J LINK
- Plan adoption dates
- 09/09/2025
Company context
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.